Home LiteratureArticle Details
PMID: 18464894 Published · epublish English Journal Article Research Support, N.I.H., Extramural Research Support, N.I.H., Intramural Research Support, Non-U.S. Gov't

Maturation of West Nile virus modulates sensitivity to antibody-mediated neutralization.

PLoS pathogens ·Vol. 4 ·No. 5 ·2008-05-09 ·Pages e1000060

Nelson S, Jost CA, Xu Q, Ess J, Martin JE, Oliphant T, Whitehead SS, Durbin AP, Graham BS, Diamond MS, Pierson TC

Abstract

West Nile virions incorporate 180 envelope (E) proteins that orchestrate the process of virus entry and are the primary target of neutralizing antibodies. The E proteins of newly synthesized West Nile virus (WNV) are organized into trimeric spikes composed of pre-membrane (prM) and E protein heterodimers. During egress, immature virions undergo a protease-mediated cleavage of prM that results in a reorganization of E protein into the pseudo-icosahedral arrangement characteristic of mature virions. While cleavage of prM is a required step in the virus life cycle, complete maturation is not required for infectivity and infectious virions may be heterogeneous with respect to the extent of prM cleavage. In this study, we demonstrate that virion maturation impacts the sensitivity of WNV to antibody-mediated neutralization. Complete maturation results in a significant reduction in sensitivity to neutralization by antibodies specific for poorly accessible epitopes that comprise a major component of the human antibody response following WNV infection or vaccination. This reduction in neutralization sensitivity reflects a decrease in the accessibility of epitopes on virions to levels that fall below a threshold required for neutralization. Thus, in addition to a role in facilitating viral entry, changes in E protein arrangement associated with maturation modulate neutralization sensitivity and introduce an additional layer of complexity into humoral immunity against WNV.

MeSH Terms
Animals Antibodies, Viral/immunology,metabolism Cell Line Chlorocebus aethiops Clinical Trials, Phase I as Topic Dose-Response Relationship, Immunologic Humans Neutralization Tests Protein Binding Protein Biosynthesis Vero Cells Viral Envelope Proteins/immunology,metabolism Virion/immunology,metabolism West Nile Fever/immunology West Nile virus/growth & development,immunology
Chemicals
Antibodies, Viral Viral Envelope Proteins
Authors & Affiliations
11 authors, click to expand affiliations / ORCID
Nelson Steevenson
Viral Pathogenesis Section, Laboratory of Viral Diseases, National Institutes of Health, Bethesda, Maryland, United States of America.
Jost Christiane A
Xu Qinq
Ess Jessica
Martin Julie E
Oliphant Theodore
Whitehead Stephen S
Durbin Anna P
Graham Barney S
Diamond Michael S
Pierson Theodore C
References (48)
48 references, click to expand
  1. Virology, pathology, and clinical manifestations of West Nile virus disease.
    Emerg Infect Dis. 2005 Aug;11(8):1174-9 PMID: 16102303
  2. N-linked glycosylation of west nile virus envelope proteins influences particle assembly and infectivity.
    J Virol. 2005 Nov;79(21):13262-74 PMID: 16227249
  3. Structural basis of West Nile virus neutralization by a therapeutic antibody.
    Nature. 2005 Sep 29;437(7059):764-9 PMID: 16193056
  4. Fusion activity of flaviviruses: comparison of mature and immature (prM-containing) tick-borne encephalitis virions.
    J Gen Virol. 1991 Jun;72 ( Pt 6):1323-9 PMID: 1710648
  5. Monoclonal antibody mapping of the envelope glycoprotein of the dengue 2 virus, Jamaica.
    Virology. 1998 Jul 5;246(2):317-28 PMID: 9657950
  6. Emerging flaviviruses: the spread and resurgence of Japanese encephalitis, West Nile and dengue viruses.
    Nat Med. 2004 Dec;10(12 Suppl):S98-109 PMID: 15577938
  7. West Nile virus recombinant DNA vaccine protects mouse and horse from virus challenge and expresses in vitro a noninfectious recombinant antigen that can be used in enzyme-linked immunosorbent assays.
    J Virol. 2001 May;75(9):4040-7 PMID: 11287553
  8. Structures of immature flavivirus particles.
    EMBO J. 2003 Jun 2;22(11):2604-13 PMID: 12773377
  9. Cryptic properties of a cluster of dominant flavivirus cross-reactive antigenic sites.
    J Virol. 2006 Oct;80(19):9557-68 PMID: 16973559
  10. Cleavage of protein prM is necessary for infection of BHK-21 cells by tick-borne encephalitis virus.
    J Gen Virol. 2003 Jan;84(Pt 1):183-191 PMID: 12533715
  11. Identification of neutralizing epitopes within structural domain III of the West Nile virus envelope protein.
    J Virol. 2002 Dec;76(24):13097-100 PMID: 12438639
  12. A topological and functional model of epitopes on the structural glycoprotein of tick-borne encephalitis virus defined by monoclonal antibodies.
    Virology. 1983 Apr 30;126(2):525-37 PMID: 6190308
  13. A West Nile virus DNA vaccine induces neutralizing antibody in healthy adults during a phase 1 clinical trial.
    J Infect Dis. 2007 Dec 15;196(12):1732-40 PMID: 18190252
  14. Structure of West Nile virus.
    Science. 2003 Oct 10;302(5643):248 PMID: 14551429
  15. DNA-based and alphavirus-vectored immunisation with prM and E proteins elicits long-lived and protective immunity against the flavivirus, Murray Valley encephalitis virus.
    Virology. 1998 Oct 10;250(1):151-63 PMID: 9770429
  16. Resuscitating mutations in a furin cleavage-deficient mutant of the flavivirus tick-borne encephalitis virus.
    J Virol. 2005 Sep;79(18):11813-23 PMID: 16140758
  17. Localization and characterization of flavivirus envelope glycoprotein cross-reactive epitopes.
    J Virol. 2004 Dec;78(24):13975-86 PMID: 15564505
  18. Structure of dengue virus: implications for flavivirus organization, maturation, and fusion.
    Cell. 2002 Mar 8;108(5):717-25 PMID: 11893341
  19. A rapid and quantitative assay for measuring antibody-mediated neutralization of West Nile virus infection.
    Virology. 2006 Mar 1;346(1):53-65 PMID: 16325883
  20. The location of asparagine-linked glycans on West Nile virions controls their interactions with CD209 (dendritic cell-specific ICAM-3 grabbing nonintegrin).
    J Biol Chem. 2006 Dec 1;281(48):37183-94 PMID: 17001080
  21. The stoichiometry of antibody-mediated neutralization and enhancement of West Nile virus infection.
    Cell Host Microbe. 2007 Apr 19;1(2):135-45 PMID: 18005691
  22. Acidotropic amines inhibit proteolytic processing of flavivirus prM protein.
    Virology. 1990 Feb;174(2):450-8 PMID: 2154882
  23. Association between the pH-dependent conformational change of West Nile flavivirus E protein and virus-mediated membrane fusion.
    J Gen Virol. 1988 Jun;69 ( Pt 6):1247-54 PMID: 3385406
  24. Proteolytic activation of tick-borne encephalitis virus by furin.
    J Virol. 1997 Nov;71(11):8475-81 PMID: 9343204
  25. Encapsidation of the flavivirus kunjin replicon RNA by using a complementation system providing Kunjin virus structural proteins in trans.
    J Virol. 1998 Jul;72(7):5967-77 PMID: 9621059
  26. A multi-hit model for the neutralization of animal viruses.
    J Gen Virol. 1978 Jan;38(1):1-19 PMID: 74400
  27. Assembly and maturation of the flavivirus Kunjin virus appear to occur in the rough endoplasmic reticulum and along the secretory pathway, respectively.
    J Virol. 2001 Nov;75(22):10787-99 PMID: 11602720
  28. Occupancy and mechanism in antibody-mediated neutralization of animal viruses.
    J Gen Virol. 2002 Sep;83(Pt 9):2091-2108 PMID: 12185262
  29. Antibody recognition and neutralization determinants on domains I and II of West Nile Virus envelope protein.
    J Virol. 2006 Dec;80(24):12149-59 PMID: 17035317
  30. Isolation and characterization of human monoclonal antibodies from individuals infected with West Nile Virus.
    J Virol. 2006 Jul;80(14):6982-92 PMID: 16809304
  31. Low pH-induced cell fusion in flavivirus-infected Aedes albopictus cell cultures.
    J Gen Virol. 1990 Aug;71 ( Pt 8):1845-50 PMID: 2167941
  32. Identification of epitopes on the E glycoprotein of Saint Louis encephalitis virus using monoclonal antibodies.
    Virology. 1983 Jul 15;128(1):118-26 PMID: 6192585
  33. A structural perspective of the flavivirus life cycle.
    Nat Rev Microbiol. 2005 Jan;3(1):13-22 PMID: 15608696
  34. Structural changes and functional control of the tick-borne encephalitis virus glycoprotein E by the heterodimeric association with protein prM.
    Virology. 1994 Jan;198(1):109-17 PMID: 8259646
  35. Neutralization and antibody-dependent enhancement of dengue viruses.
    Adv Virus Res. 2003;60:421-67 PMID: 14689700
  36. Structure of immature West Nile virus.
    J Virol. 2007 Jun;81(11):6141-5 PMID: 17376919
  37. The Murray Valley encephalitis virus prM protein confers acid resistance to virus particles and alters the expression of epitopes within the R2 domain of E glycoprotein.
    Virology. 1992 Dec;191(2):921-31 PMID: 1280384
  38. A model for neutralization of viruses based on antibody coating of the virion surface.
    Curr Top Microbiol Immunol. 2001;260:109-43 PMID: 11443871
  39. Pathogenesis of West Nile Virus infection: a balance between virulence, innate and adaptive immunity, and viral evasion.
    J Virol. 2006 Oct;80(19):9349-60 PMID: 16973541
  40. Induction of epitope-specific neutralizing antibodies against West Nile virus.
    J Virol. 2007 Nov;81(21):11828-39 PMID: 17715236
  41. Membrane fusion process of Semliki Forest virus. II: Cleavage-dependent reorganization of the spike protein complex controls virus entry.
    J Cell Biol. 1992 Jan;116(2):349-57 PMID: 1730759
  42. West Nile virus discriminates between DC-SIGN and DC-SIGNR for cellular attachment and infection.
    J Virol. 2006 Feb;80(3):1290-301 PMID: 16415006
  43. Development of a humanized monoclonal antibody with therapeutic potential against West Nile virus.
    Nat Med. 2005 May;11(5):522-30 PMID: 15852016
  44. Identification of an epitope on the dengue virus membrane (M) protein defined by cross-protective monoclonal antibodies: design of an improved epitope sequence based on common determinants present in both envelope (E and M) proteins.
    Arch Virol. 1999;144(12):2313-30 PMID: 10664386
  45. The neutralizing antibody response against West Nile virus in naturally infected horses.
    Virology. 2007 Mar 15;359(2):336-48 PMID: 17055550
  46. Recombinant vaccinia virus producing the prM and E proteins of yellow fever virus protects mice from lethal yellow fever encephalitis.
    Virology. 1992 Mar;187(1):290-7 PMID: 1736531
  47. West Nile virus in complex with the Fab fragment of a neutralizing monoclonal antibody.
    Proc Natl Acad Sci U S A. 2006 Aug 15;103(33):12400-4 PMID: 16895988
  48. Oligomeric rearrangement of tick-borne encephalitis virus envelope proteins induced by an acidic pH.
    J Virol. 1995 Feb;69(2):695-700 PMID: 7529335
Article Info
Journal
PLoS pathogens
Abbr.
PLoS Pathog
ISSN
1553-7374
Published
2008-05-09
Epub
2008-00-09
Pages
e1000060
Language
English
Region
United States
NLM ID
101238921
PMCID
PMC2330159
Subset
IM
Grants
NIAID NIH HHS · U01 AI061373 · United States
Intramural NIH HHS · United States
Analysis Services
Analysis Services

Contact

No. 2 Wenbo Road, Zhangqiu District, Jinan, Shandong

Qilu Normal University · Genelibs Bioinformatics Lab

750 Shunhua Rd, Jinan

2F, Bldg F, University Science Park

Tel: 0531-88819269

WeChat Official Account

Follow our WeChat subscription account for real-time updates and the latest in medical and biological research.


Business Email

E-mail: product@genelibs.com